Archive for month: August, 2019
Amid escalating concerns over antibiotic resistance, several big drug makers are creating a new $1 billion for-profit venture to acquire or invest in small antibiotic companies and their nascent products, according to two people familiar with the plans.
Click HERE to see the article on STAT.
Botanix Pharmaceuticals Limited (ASX:BOT)—a clinical stage cannabinoid company—has received firm commitments for a $40 million placement led by specialist US-based biotech investment funds and leading US institutional investors.
The $40 million in funding—which was offered at a price of $0.21 per fully paid ordinary share—will be used to support the company’s cannabinoid clinical development and research portfolio.
Click HERE to read the article on The Green Fund.